A Comprehensive Systematic Review of The Relationship between Epstein-Barr Virus (EBV) Exposure and the Development of Non-Keratinizing Nasopharyngeal Carcinoma
Keywords:
Epstein-Barr Virus, Nasopharyngeal Carcinoma, Non-Keratinizing Carcinoma, VCA-IgA, Plasma EBV DNA, Prognosis, Screening, Meta-AnalysisAbstract
Introduction: Nasopharyngeal carcinoma (NPC) is a malignancy with a distinct geographical distribution, showing high prevalence in endemic regions like Southern China and Southeast Asia. The Epstein-Barr virus (EBV) is a well-established oncogenic driver, particularly for non-keratinizing NPC subtypes (WHO Types II/III). Understanding the precise relationship between EBV exposure, its biomarkers, and NPC development is critical for improving early detection, prognosis, and treatment strategies (Banko et al., 2021; Chan et al., 2004).
Methods: This report synthesizes evidence from a systematic review of 80 sources, including meta-analyses, cohort studies, randomized controlled trials, and case-control studies. Data extraction focused on study design, population characteristics, EBV exposure definition (serological markers, plasma EBV DNA, genetic variants), NPC histological classification, measures of association, confounders, and study quality. Quantitative synthesis was performed on diagnostic accuracy, prognostic value, and screening effectiveness.
Results: The evidence demonstrates a near-universal association between EBV and non-keratinizing NPC in endemic regions, with EBV positivity rates reaching 100%. Serological markers like VCA-IgA show high diagnostic accuracy (pooled sensitivity 0.91, specificity 0.92), with multi-marker panels (e.g., VCA-IgA + EA-IgA + Rta-IgG) providing superior performance. Plasma EBV DNA detection offers excellent diagnostic (sensitivity 89.1%, specificity 85.0%) and superior prognostic utility. High-risk EBV genetic variants (e.g., BALF2 I613V, OR=7.9) are strongly linked to NPC risk. Pre-treatment and, more powerfully, post-treatment plasma EBV DNA levels are significant independent prognostic factors for overall, progression-free, and distant metastasis-free survival (e.g., HR up to 129.07 for post-treatment DNA). EBV-based screening programs in endemic areas have demonstrated a significant 30% reduction in NPC mortality (Chen et al., 2024).
Discussion: The robust association underscores EBV's central role in non-keratinizing NPC carcinogenesis. The diagnostic and prognostic hierarchy favors plasma EBV DNA and multi-parameter serology. Geographic, methodological, and histological heterogeneity explain variations in reported associations. EBV biomarkers are pivotal for risk stratification, screening, treatment monitoring, and prognostication.
Conclusion: EBV is a fundamental etiological agent for non-keratinizing NPC. Integrating EBV serology and plasma EBV DNA into public health screening programs in endemic regions and into clinical management protocols for diagnosis, prognostic stratification, and treatment monitoring is strongly supported by evidence. Future research should focus on standardizing assays, elucidating molecular mechanisms, and validating findings in non-endemic populations.
References
A. Banko, D. Miljanovic, I. Lazarević, and A. Cirkovic. “A Systematic Review of Epstein–Barr Virus Latent Membrane Protein 1 (LMP1) Gene Variants in Nasopharyngeal Carcinoma.” Pathogens, 2021.
A. Chan, B. Ma, Y. Lo, S. Leung, W. Kwan, E. Hui, T. Mok, et al. “Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring with Plasma Epstein-Barr Virus DNA.” Journal of Clinical Oncology, 2004.
A. Chan, E. Hui, R. Ngan, S. Tung, A. Cheng, W. Ng, V. Lee, et al. “Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial.” Journal of Clinical Oncology, 2018.
A. Lee, V. Lee, W. Ng, P. Strojan, N. Saba, A. Rinaldo, S. Willems, J. Rodrigo, A. Forastiere, and A. Ferlito. “A Systematic Review and Recommendations on the Use of Plasma EBV DNA for Nasopharyngeal Carcinoma.” European Journal of Cancer, 2021.
Anna Merlo, Riccardo Turrini, R. Dolcetti, P. Zanovello, A. Amadori, and A. Rosato. “Adoptive Cell Therapy Against EBV-Related Malignancies: A Survey of Clinical Results,” 2008.
Antonia Taiane Lopes de Moraes, Erison Santana dos Santos, C. Pedroso, Rafael Tomaz Gomes, Renata Ferrarotto, and A. Santos-Silva. “Human Oncogenic Viruses: A Focus on Head and Neck Carcinogenesis: A Systematic Review and Meta-Analysis.” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2024.
C. Lertbutsayanukul, D. Kannarunimit, A. Prayongrat, C. Chakkabat, S. Kitpanit, and P. Hansasuta. “Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients During Treatment with Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy.” Radiology and Oncology, 2018.
Changxin Song, and Shujuan Yang. “A Meta-Analysis on the EBV DNA and VCA-IgA in Diagnosis of Nasopharyngeal Carcinoma.” Pakistan Journal of Medical Sciences, 2013.
Chenglong Huang, Gao-Yuan Wang, Jia-Hao Lou, Lin Chen, Qingjie Li, Kunpeng Li, Xiao-Yu Liang, et al. “Oral Chemotherapy Versus Observation Alone in Nasopharyngeal Carcinoma Patients with Persistently Detected Circulating Cell-Free Epstein-Barr Virus DNA During Follow-up.” Radiotherapy and Oncology, 2023.
C-L. Huang. “913P Oral Chemotherapy Versus Observation Alone in Nasopharyngeal Carcinoma Patients with Persistently Detected Circulating Cell-Free Epstein-Barr Virus DNA During Follow-up.” Annals of Oncology, 2023.
Deborah Lenoci, C. Resteghini, M. Serafini, F. Pistore, S. Canevari, B. Ma, S. Cavalieri, A. Trama, L. Licitra, and L. De Cecco. “Abstract 4529: The Tumor Molecular Landscape of Nasopharyngeal Carcinoma (NPC) in Endemic and Non Endemic Areas.” Cancer Research, 2023.
Deborah Lenoci, C. Resteghini, M. Serafini, F. Pistore, Silvana Canevari, B. Ma, S. Cavalieri, et al. “Tumor Molecular Landscape of Epstein-Barr Virus (EBV) Related Nasopharyngeal Carcinoma in EBV-Endemic and Non-Endemic Areas: Implications for Improving Treatment Modalities.” Translational Research : The Journal of Laboratory and Clinical Medicine, 2023.
Deniz Bakkalci, Y. Jia, Joanne R. Winter, Joanna E. A. Lewis, G. Taylor, and H. Stagg. “Risk Factors for Epstein Barr Virus-Associated Cancers: A Systematic Review, Critical Appraisal, and Mapping of the Epidemiological Evidence.” Journal of Global Health, 2020.
Diógenes Germano Fornel, T. Ferrisse, A. B. de Oliveira, and C. R. Fontana. “Photodynamic Therapy Can Modulate the Nasopharyngeal Carcinoma Microenvironment Infected with the Epstein–Barr Virus: A Systematic Review and Meta-Analysis.” Biomedicines, 2023.
E. Hui, B. Ma, W. Lam, Allen Chan, F. Mo, Q. Ai, A. King, et al. “Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer.” Clinical Cancer Research, 2021.
E. N. S. Engku Abd Rahman, A. Irekeola, R. Shueb, R. Mohamud, N. Mat Lazim, B. Abdullah, and Y. Y. Chan. “Prevalence of Epstein-Barr Virus Infection in Individuals with Nasopharyngeal Carcinoma in Malaysia: The First Systematic Review and Meta-Analysi.” Tropical Biomedicine, 2022.
Feng Chen, Ke Liu, Qihong Huang, Zhi-wei Liu, and Su-Mei Cao. “[Comparison of Incidence of Nasopharyngeal Carcinoma in Populations with Different Fluctuation Modes of Immunoglobulin A Antibody Levels Against Epstein-Barr Virus Capsid Antigen].” Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine], 2012.
G. Fountzilas, C. Tolis, A. Kalogera-Fountzila, C. Karanikiotis, M. Bai, D. Misailidou, E. Samantas, et al. “Induction Chemotherapy with Cisplatin, Epirubicin, and Paclitaxel (CEP), Followed by Concomitant Radiotherapy and Weekly Paclitaxel for the Management of Locally Advanced Nasopharyngeal Carcinoma.” Strahlentherapie Und Onkologie (Print), 2005.
H. Su, F. Jin, Y. Li, W. Wu, K. Liu, C. Zhao, L. Liu, J. Long, Q. He, and T. Bi. “Comparative Analysis of Clinical Results of Compared With TPF Induction of Chemotherapy and PF Adjuvant Chemotherapy Combined With Cisplatin Radiochemotherapy for Locally Advanced Nasopharyngeal Carcinoma.” International Journal of Radiation Oncology, Biology, Physics, 2021.
Han Liu, Lin Lei, Song Song, Xianyi Geng, Kaihao Lin, Ni Li, Wanqing Chen, Ji Peng, and Jiansong Ren. “The Serological Diagnostic Value of EBV-Related IgA Antibody Panels for Nasopharyngeal Carcinoma: A Diagnostic Test Accuracy Meta-Analysis.” BMC Cancer, 2024.
Hana Ratnawati, Ardo Sanjaya, Aldrich Christiandy, L. Young, and Sascha Ott. “The Ubiquitin–Proteasome System Is an Important Driver of EBV-Associated Nasopharyngeal Carcinoma Progression: A Meta-Analysis of Transcriptomics Data.” bioRxiv, 2025.
“HEAD AND NECK: HUMAN PAPILLOMA VIRUS ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA (WK MYDLARZ AND C FAKHRY, SECTION Human Papillomavirus‑Related Carcinomas of the Sinonasal Tract,” 2022.
Hongling Qu, Yuli Huang, Shufen Zhao, Yuanqing Zhou, and Weibiao Lv. “Prognostic Value of Epstein–Barr Virus DNA Level for Nasopharyngeal Carcinoma: A Meta-Analysis of 8128 Cases.” European Archives of Oto-Rhino-Laryngology, 2019.
Imane El Alami, Amina Gihbid, H. Charoute, Wafa Khaali, Selma Mohamed Brahim, N. Tawfiq, R. Cadi, K. Belghmi, M. El Mzibri, and M. Khyatti. “Prognostic Value of Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma: A Meta-Analysis.” The Pan African Medical Journal, 2022.
J. A. Miller, Zhiwei Liu, B. Pinsky, Quynh-Thu Le, Tong Li, Kelly J. Yu, A. Hildesheim, and S. Cao. “Optimization and Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the Guangdong Randomized Trial.” Cancer Epidemiology, Biomarkers and Prevention, 2024.
J. Bei, Wen-Hui Su, C. Ng, Kai Yu, Y. Chin, P. Lou, W. Hsu, et al. “A GWAS Meta-Analysis and Replication Study Identifies a Novel Locus Within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry.” Cancer Epidemiology, Biomarkers and Prevention, 2015.
J. Chow, Anne W. M. Lee, C. H. Wong, W. Ng, Zhiwei Liu, J. Tay, K. Loh, et al. “Epstein-Barr Virus Directed Screening for Nasopharyngeal Carcinoma in Individuals with Positive Family History: A Systematic Review.” Oral Oncology, 2022.
J. Guigay. “Advances in Nasopharyngeal Carcinoma.” Current Opinion in Oncology, 2008.
J. Miller, Z. Liu, B. Pinsky, Q. T. Le, T. Li, S. Cao, and A. Hildesheim. “Local Cost-Effectiveness of Nasopharyngeal Carcinoma Screening Strategies in Southern China: Secondary Analysis of the PRO-NPC-001 Cluster-Randomized Trial.” International Journal of Radiation Oncology, Biology, Physics, 2023.
Jacob A. Miller, M. Sahoo, F. Yamamoto, ChunHong Huang, Hannah Wang, J. Zehnder, Q. Le, and B. Pinsky. “Multiplex Epstein-Barr Virus BALF2 Genotyping Detects High-Risk Variants in Plasma for Population Screening of Nasopharyngeal Carcinoma.” Molecular Cancer, 2022.
Jacob A. Miller, M. Sahoo, F. Yamamoto, ChunHong Huang, Hannah Wang, J. Zehnder, Quynh-Thu Le, and B. Pinsky. “Multiplex Epstein-Barr Virus BALF2 Genotyping Detects High-Risk Variants in Plasma for Population Screening of Nasopharyngeal Carcinoma.” Molecular Cancer, 2022.
Jacob A. Miller, Q. Le, B. Pinsky, and Hannah Wang. “Cost-Effectiveness of Nasopharyngeal Carcinoma Screening with Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide.” Journal of the National Cancer Institute, 2020.
Jiang Li, Qiu-Yan Chen, Jia He, Ze-Lei Li, Xiao-feng Tang, Shi-ping Chen, Chuan-miao Xie, et al. “Phase I Trial of Adoptively Transferred Tumor-Infiltrating Lymphocyte Immunotherapy Following Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.” Oncoimmunology, 2015.
Jiazhu Hu, Jie Tan, Yanjin He, Ji-shi Li, Yihao Li, and Xiaolong Cao. “Radiotherapy Combined with AiDi for Asopharynx Cancer and the Prognostic Factor,” 2013.
Jing Zhang, Chi Shu, Yanlin Song, Qingfang Li, Jingwen Huang, and Xuelei Ma. “Epstein–Barr Virus DNA Level as a Novel Prognostic Factor in Nasopharyngeal Carcinoma.” Medicine, 2016.
Joanne R. Winter, C. Jackson, Joanna E. A. Lewis, G. Taylor, Olivia G Thomas, and H. Stagg. “Predictors of Epstein-Barr Virus Serostatus and Implications for Vaccine Policy: A Systematic Review of the Literature.” Journal of Global Health, 2020.
K. Al-Saleh, A. El-Basmi, A. Hussein, F. Alshaflan, and M. El-Sherify. “Randomized Phase III Study in EBV Positive Locally Advanced Nasopharyngeal Carcinoma Treated with Concurrent Chemo-Radiotherapy with or Without Anti-Viral Drug.” Annals of Oncology, 2018.
K. C. Chan, E. C. Hung, A. S. Cheng, F. P. Lai, Andrew C. Van Hesselt, J. Woo, P. Chan, S. Leung, A. Chan, and Y. Lo. “A Prospective Trial of Plasma EBV DNA for the Screening of Nasopharyngeal Carcinoma,” 2010.
Ka Wo Wong, K. Hui, Ki Pui Lam, D. Kwong, Maria Li Lung, Wanling Yang, and A. Chiang. “Meta-Analysis of Epstein-Barr Virus Genomes in Southern Chinese Identifies Genetic Variants and High Risk Viral Lineage Associated with Nasopharyngeal Carcinoma.” PLoS Pathogens, 2024.
Kaiqi Lan, Jingrong Mao, Xuesong Sun, Suchen Li, Siyi Xie, Rui Sun, Sailan Liu, and Haiqiang Mai. “Combined Pre-Treatment and Middle-Treatment Epstein–Barr Virus DNA Load Contributes to Prognostication and Treatment Modification in Nasopharyngeal Carcinoma Patients.” Therapeutic Advances in Medical Oncology, 2024.
Kazi Anisha Islam, Larry Ka-Yue Chow, N. Kam, Ying Wang, Chiang Leung Chi, H. Choi, Yun-Fei Xia, A. Lee, W. Ng, and W. Dai. “Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature.” Cancers, 2022.
Lin Lai, Xinyu Chen, Chuxiao Zhang, Xishan Chen, Li Chen, Ge Tian, and Xiao-dong Zhu. “Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis.” Frontiers in Oncology, 2021.
Liting Liu, M. Chua, Y. Tao, L. Tang, and H. Mai. “Optimal Sequencing of Chemotherapy with Chemoradiotherapy Based on TNM Stage Classification and EBV DNA in Locoregionally Advanced Nasopharyngeal Carcinoma.” Cancer Communications, 2019.
Liu Yimin, He Yan, Wu Yan-feng, L. Kai, and W. Xiao-ping. “Effect of Adoptive Immunotherapy with Auto-Cytokine Induced Killer Cells on Tumor Markers and General Condition of Patients with Nasopharyngeal Carcinoma,” 2011.
M. Abusalah, A. Irekeola, Rafidah Hanim Shueb, Mu’taman Jarrar, and Chan Yean Yean. “Prognostic Epstein-Barr Virus (EBV) miRNA Biomarkers for Survival Outcome in EBV-Associated Epithelial Malignancies: Systematic Review and Meta-Analysis.” PLoS ONE, 2022.
M. Farooqi, Unaiza Faizan, Saad Ur Rahman, Hassaan Imtiaz, M. Arshad, A. Farooqui, Zahoor Ahmed, et al. “Emerging Role of Adoptive T Cell Therapy for EBV Induced Nasopharyngeal Carcinoma (NPC) - a Systematic Review,” 2020.
M. Ji, W. Sheng, W. Cheng, M. Ng, B. Wu, X. Yu, K. Wei, et al. “Incidence and Mortality of Nasopharyngeal Carcinoma: Interim Analysis of a Cluster Randomized Controlled Screening Trial (PRO-NPC-001) in Southern China.” Annals of Oncology, 2019.
Mei Lian. “Combining Epstein-Barr Virus Antibodies for Early Detection of Nasopharyngeal Carcinoma: A Meta-Analysis.” Auris, Nasus, Larynx, 2022.
MSc Marisa D. Muckian, PhD Ting Shi, MSc Vesa Qarkaxhija, Simran Kapoor BSc, Tomos Morgan, BMedSci, Prof. Helen, and PhD R. Stagg. “Equity in Protection: Bridging Global Data Gaps for an EBV Vaccine - a Systematic Review and Meta-Analysis.” medRxiv, 2025.
Nur Mazidah Haji Noor Mohamed, R. B. S. M. N. Mydin, Hanani Che Halim, and M. Musa. “A Systematic Review on Clinico-Aetiopathological Trends of Nasopharyngeal Cancer in Asia.” Indian Journal of Otolaryngology and Head & Neck Surgery, 2023.
P. Bossi, A. Chan, L. Licitra, A. Trama, E. Orlandi, E. Hui, J. Halámková, et al. “Nasopharyngeal Carcinoma: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.” Annals of Oncology, 2020.
P. Fang, Xiaohong Li, Qun Sha, Kun-ling Zhang, and Qingxia Zhou. “[Using PCR Method to Study the EB Virus DNA in NPC].” Lin Chuang Er Bi Yan Hou Ke Za Zhi = Journal of Clinical Otorhinolaryngology, 2004.
Pei-yu Huang, Zong-Liang Zhong, D. Luo, H. Mai, Ming-Yuan Chen, Yan-Xian Li, Jing Yang, and H. Mo. “Paired Study of 172 Cases of Nasopharyngeal Carcinoma with or Without Dermatomyositis.” Acta Oto-Laryngologica, 2014.
Qiu-Yan Chen, H. Mai, Dong-Ping Chen, Chao-su Hu, Kunyu Yang, Jiyu Wen, Jingao Li, et al. “Four-Year Overall Survival Follow-up and Dynamic EBV Titer Analysis of Toripalimab Versus Placebo in Combination with Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (r/m NPC).” Journal of Clinical Oncology, 2024.
Rosalie Machado, J. Khaymovich, P. Costantino, and T. Tham. “Detection of HPV16, HPV18, P16, and E6/E7 MRNA in Nasopharyngeal Cancer: A Systematic Review and Meta-Analysis.” bioRxiv, 2018.
S. Muthiah, and Lye Ms. “EPSTEIN-BARR VIRUS (EBV) AND ITS ASSOCIATION WITH NASOPHARYNGEAL CARCINOMA (NPC): A SYSTEMATIC REVIEW,” 2016.
Shan Li, Yan Deng, Xi Li, Qiao-pei Chen, X. Liao, and X. Qin. “Diagnostic Value of Epstein-Barr Virus Capsid Antigen-IgA in Nasopharyngeal Carcinoma: A Meta-Analysis.” Chinese Medical Journal, 2010.
Si-Qi Tang, Lei Chen, Wen-Fei Li, A. Chan, Shao Hui Huang, M. Chua, B. O'Sullivan, et al. “Identifying Optimal Clinical Trial Candidates for Locoregionally Advanced Nasopharyngeal Carcinoma: Analysis of 9,468 Real-World Cases and Validation by Two Phase 3 Multicentre, Randomised Controlled Trial.” Radiotherapy and Oncology, 2021.
T. Tham, Rosalie Machado, D. Russo, S. W. Herman, Sushma Teegala, and P. Costantino. “Viral Markers in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis on the Detection of p16INK4a, Human Papillomavirus (HPV), and Ebstein-Barr Virus (EBV).” American Journal of Otolaryngology, 2020.
Tianhao Liang, Weixing Liu, Junyang Xie, Yi-yun Wang, Gui Chen, W. Liao, Lijuan Song, and Xiaowen Zhang. “Serum EA-IgA and d-Dimer, but Not VCA-IgA, Are Associated with Prognosis in Patients with Nasopharyngeal Carcinoma: A Meta-Analysis.” Cancer Cell International, 2021.
Ting Liu, Zhi-hong Zheng, Jie Pan, L. Pan, and Li-hong Chen. “Prognostic Role of Plasma Epstein-Barr Virus DNA Load for Nasopharyngeal Carcinoma: A Meta-Analysis.” Clinical and Investigative Medicine. Medecine Clinique Et Experimentale, 2017.
V. Lee, D. Kwong, T. Leung, H. Choi, B. O'Sullivan, V. Lai, C. Tong, et al. “5-Year Results of the Prognostic Roles of Serial Post-Intensity-Modulated Radiation Therapy Undetectable Plasma EBV DNA for Non-Metastatic Nasopharyngeal Carcinoma.” International Journal of Radiation Oncology, Biology, Physics, 2018.
W. Chen, X. Yu, Y.-Q. Lu, R. Pfeiffer, W. Ling, S. Xie, Z.-C. Wu, et al. “Effect of EBV Serology-Based Screening Program on NPC Mortality: A Cluster Randomized Controlled Trial.” medRxiv, 2022.
W. Jia, and H. Qin. “Non-Viral Environmental Risk Factors for Nasopharyngeal Carcinoma: A Systematic Review.” Seminars in Cancer Biology, 2012.
Weixing Liu, Gui Chen, Xin-Hua Gong, Yingqi Wang, Yaoming Zheng, Xiaodong Liao, W. Liao, Lijuan Song, Jun Xu, and Xiaowen Zhang. “The Diagnostic Value of EBV-DNA and EBV-Related Antibodies Detection for Nasopharyngeal Carcinoma: A Meta-Analysis.” Cancer Cell International, 2021.
Wen-Jie Chen, Xia Yu, Yu-Qiang Lu, Ruth M. Pfeiffer, W. Ling, S. Xie, Zhi-Cong Wu, et al. “Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.” Journal of Clinical Oncology, 2024.
Wenli Zhang, Jiang-Bo Zhang, Tong-Min Wang, Yanxia Wu, Yong-Qiao He, W. Xue, Ying Liao, et al. “Genomic Landscape of Epstein-Barr Virus in Familial Nasopharyngeal Carcinoma.” Journal of General Virology, 2022.
Wenna Zhang, Yupei Chen, Lei Chen, R. Guo, G. Zhou, Ling-long Tang, Y. Mao, et al. “The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal Carcinoma: The Dawn of a New Era?” Medicine, 2015.
X. Qian, Haizhu Chen, and Y. Tao. “Biomarkers Predicting Clinical Outcomes in Nasopharyngeal Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.” Frontiers in Immunology, 2023.
Xia Chen, S. Liang, Wenling Zheng, Zhi-jun Liao, T. Shang, and Wenli Ma. “Meta-Analysis of Nasopharyngeal Carcinoma Microarray Data Explores Mechanism of EBV-Regulated Neoplastic Transformation.” BMC Genomics, 2008.
Xulin Xie, Yupei Ren, Kun Wang, and B. Yi. “Molecular Prognostic Value of Circulating Epstein-Barr Viral DNA in Nasopharyngeal Carcinoma: A Meta-Analysis of 27,235 Cases in the Endemic Area of Southeast Asia.” Genetic Testing and Molecular Biomarkers, 2019.
Y. Chin. “Genome-Wide Association Studies of Nasopharyngeal Carcinoma in the Malaysian Chinese Cohort Using Single Genes, Meta-Analysis and Pathway Analysis Approaches / Chin Yoon Ming,” 2017.
Y. Zhang, Wen-Fei Li, Y. Mao, R. Guo, L. Tang, Hao-ran Peng, Ying Sun, Qing Liu, Lei Chen, and Jun Ma. “Risk Stratification Based on Change in Plasma Epstein-Barr Virus DNA Load After Treatment in Nasopharyngeal Carcinoma.” OncoTarget, 2016.
Yi Zhao, Yan Wang, S. Zeng, and Xinrong Hu. “LMP1 Expression Is Positively Associated with Metastasis of Nasopharyngeal Carcinoma: Evidence from a Meta-Analysis.” Journal of Clinical Pathology, 2011.
Yiwei Feng, W. Xia, Guangyao He, R. Ke, Lei Liu, M. Xie, A. Tang, and X. Yi. “Accuracy Evaluation and Comparison of 14 Diagnostic Markers for Nasopharyngeal Carcinoma: A Meta-Analysis.” Frontiers in Oncology, 2020.
Yu Liu, Z. Fang, Li Liu, Shujuan Yang, and Lishi Zhang. “Detection of Epstein-Barr Virus DNA in Serum or Plasma for Nasopharyngeal Cancer: A Meta-Analysis.” Genetic Testing and Molecular Biomarkers, 2011.
Yu-Mei Shi, Xintian Qin, Xingchen Peng, Aiping Zeng, Jingao Li, Chuanben Chen, S. Qiu, et al. “Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study.” The Lancet Regional Health - Western Pacific, 2022.
Yupei Chen, Wenna Zhang, Lei Chen, L. Tang, Y. Mao, Wen-Fei Li, Xu Liu, et al. “Effect of Latent Membrane Protein 1 Expression on Overall Survival in Epstein-Barr Virus-Associated Cancers: A Literature-Based Meta-Analysis.” OncoTarget, 2015.
Zhen Wu, Xiaoling Zhang, Pinjing Liu, Aiyou Wei, W. Ouyang, and Shengjun Xiao. “Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.” Oxidative Medicine and Cellular Longevity, 2022.
Zhiwei Liu, M. Ji, Qihong Huang, F. Fang, Qing Liu, W. Jia, Xiang Guo, et al. “Two Epstein-Barr Virus-Related Serologic Antibody Tests in Nasopharyngeal Carcinoma Screening: Results from the Initial Phase of a Cluster Randomized Controlled Trial in Southern China.” American Journal of Epidemiology, 2013.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhammad Rifki Kholis Putra, Muhammad Abduh Firdaus (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
